SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Focused Visit (Care-plan review) — Evel Knievel

PatientEvel Knievel
Date of birth1968-10-17
IdentifiersMRN HR-RB001-SYN; SSN (made up) 000-01-4927
Document date2026-08-17
AuthorDale Rasmussen, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Test of cure for hepatitis C and six-month liver cancer surveillance. [S]

History of Present Illness

Mr. Knievel returns 13 weeks after his last dose of sofosbuvir-velpatasvir. The surveillance ultrasound a week ago showed no liver lesion. He had the zoledronic acid infusion eleven weeks ago, with a day of aches afterwards. His eye examination in June showed no diabetic retinopathy. He has had no alcohol since February. He takes carvedilol 12.5 mg daily. Pain is about 4 of 10 and he walks 30 minutes most days. He has had no falls, abdominal swelling, black stools, confusion or yellow eyes. He has had no thoughts of self-harm. [S]

ElementDetail
CureHCV RNA not detected 13 weeks after treatment
SurveillanceUltrasound a week ago: no lesion; alpha-fetoprotein 3.4 ng/mL
Liver functionChild-Pugh A5; MELD-Na 6
BoneZoledronic acid given eleven weeks ago

Review of Systems

SystemResultFinding
ConstitutionalNegativeEnergy good; weight steady
GastrointestinalNegativeNo abdominal swelling, black stools or vomiting of blood
MusculoskeletalPositiveHip and knee pain, 4 of 10
NeurologicalNegativeNo confusion or tremor
EndocrineNegativeNo low glucose readings
PsychiatricNegativeMood good; PHQ-9 3; no thoughts of self-harm

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Metformin 1000 mg oral tablet, one tablet by mouth twice daily with mealsOne tablet twice daily with breakfast and supperOral route2021-03-01activeS
Ibuprofen 800 mg oral tablet, one tablet three times a day for joint and back painOne tablet three times a dayOral route2024-06-01 to 2026-01-12completedS
Omeprazole 20 mg delayed-release oral capsule, one capsule daily for indigestion from ibuprofenOne capsule daily before breakfastOral route2024-06-01 to 2026-01-12completedS
Acetaminophen 500 mg oral tablet, two tablets by mouth up to twice a day as needed for pain, no more than 2 g a dayTwo tablets up to twice a day as needed; no more than 2 g a dayOral route2026-01-12activeS
Diclofenac sodium 1% topical gel, 4 g to the knees up to four times a day4 g to each knee up to four times a dayTopical route2026-01-12activeS
Carvedilol 6.25 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-01-26 to 2026-02-23completedS
Carvedilol 12.5 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-02-23activeS
Atorvastatin 20 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-01-26activeS
Sofosbuvir 400 mg and velpatasvir 100 mg oral tablet, one tablet daily for 12 weeksOne tablet daily for 12 weeksOral route2026-02-23 to 2026-05-17completedS
Cholecalciferol (vitamin D3) 50 mcg (2000 units) oral capsule, one capsule dailyOne capsule dailyOral route2026-02-23activeS
Zoledronic acid 5 mg in 100 mL, intravenous infusion over at least 15 minutes, once a yearOnce a yearIntravenous route2026-06-01activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-08-17Body height178cmS
2026-08-17Body weight82.6kgS
2026-08-17Body mass index (BMI) [Ratio]26.1kg/m2S
2026-08-17Systolic blood pressure120mm[Hg]S
2026-08-17Diastolic blood pressure74mm[Hg]S
2026-08-17Heart rate60/minS
2026-08-17Respiratory rate14/minS
2026-08-17Body temperature36.6CelS
2026-08-17Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-08-17Hemoglobin [Mass/volume] in Blood14.4g/dL13.5-17.5 g/dLNormalS
2026-08-17Leukocytes [#/volume] in Blood by Automated count5.210*3/uL4-11 10*3/uLNormalS
2026-08-17Platelets [#/volume] in Blood by Automated count13410*3/uL150-400 10*3/uLLowS
2026-08-17Creatinine [Mass/volume] in Serum or Plasma0.88mg/dL0.74-1.35 mg/dLNormalS
2026-08-17Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M100mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-08-17Glucose [Mass/volume] in Serum or Plasma112mg/dL70-99 mg/dLHighS
2026-08-17Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L7-55 U/LNormalS
2026-08-17Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma26U/L8-48 U/LNormalS
2026-08-17Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma92U/L40-129 U/LNormalS
2026-08-17Bilirubin.total [Mass/volume] in Serum or Plasma0.8mg/dL0.1-1.2 mg/dLNormalS
2026-08-17Albumin [Mass/volume] in Serum or Plasma4g/dL3.5-5 g/dLNormalS
2026-08-17INR in Platelet poor plasma by Coagulation assay1{INR}0.9-1.1NormalS
2026-08-17Hepatitis C virus RNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection0[IU]/mLNot detected is reported as 0; lower limit of quantification 15 IU/mLNormalS
2026-08-17Alpha-1-Fetoprotein [Mass/volume] in Serum or Plasma3.4ng/mL<=8.3 ng/mLNormalS
2026-08-17Hemoglobin A1c/Hemoglobin.total in Blood6.3%Below 5.7% is normal; individual goal below 7%; may read falsely low in cirrhosisHighS
2026-08-17Glucose management indicator6.8%Individual goal below 7%NormalS
2026-08-17Total score [AUDIT-C]0{score}S
2026-08-17Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S
2026-08-17Pain severity - 0-10 verbal numeric rating [Score] - Reported4{score}S

Physical Exam

Vital signs recorded on 2026-08-17; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 82.6 kg; blood pressure 120/74, pulse 60
SkinA few spider angiomas; no jaundice
AbdomenSpleen tip palpable; no ascites
NeurologicalNo asterixis; gait steady

Problems

ProblemClinical statusVerificationCodeProvenance
Raised transaminases (ALT 88, AST 96 U/L) and low platelets (118) on today's tests, with spider angiomas and palmar erythema, in a man of 57 who received many blood transfusions after crashes before 1992 and drinks most evenings: chronic liver disease, most likely hepatitis C, must be excluded. Hepatitis C antibody with reflex RNA, hepatitis A and B serology, HIV, liver ultrasound and hepatology review orderedresolvedconfirmed R74.01S — Synthetic presenting problem; no symptom or result of his real illness was made public. Superseded at the hepatology consultation.
Chronic hepatitis C, genotype 1a, treatment-naive, HCV RNA 2.35 million IU/mL, likely acquired through blood transfusions after crashes; synthetic modern detail linked to his publicly reported transfusion-acquired hepatitis Cresolvedconfirmed B18.2S — Synthetic genotype, viral load and timing; his hepatitis C and its likely transfusion source are documented (D).
Compensated cirrhosis from hepatitis C, with alcohol as a cofactor: liver stiffness 26.8 kPa, FIB-4 4.94, nodular liver and a 14.2 cm spleen on ultrasound, platelets 118; Child-Pugh A5, MELD-Na 8; no ascites, encephalopathy, jaundice or bleedingactiveconfirmed K74.69S — Synthetic stage of liver disease linked to his documented hepatitis C and later liver transplant.
Clinically significant portal hypertension in compensated cirrhosis (liver stiffness 25 kPa or more), treated with carvedilol without screening endoscopy (Baveno VII)activeconfirmed K76.6S — Synthetic finding at the hepatology consultation.
Type 2 diabetes on metformin, A1c 7.4%activeconfirmed E11.65S — Synthetic; diabetes is documented only in his last years (D), and placing it at 57 is a synthetic choice.
Chronic pain in the back, hips, pelvis and knees after dozens of fractures from stunt crashes, including a broken pelvis; ibuprofen stopped, and managed without oral NSAIDs or opioidsactiveconfirmed G89.29S — Synthetic pain at the index age, anchored to his documented fractures and the pain of his later years.
Osteoporosis in a man with cirrhosis, prior heavy alcohol use and dozens of old fractures: femoral neck T-score -2.6, lumbar spine -1.9activeconfirmed M81.8S — Synthetic bone density result.
Vitamin D deficiency (25-hydroxyvitamin D 17 ng/mL)resolvedconfirmed E55.9S — Synthetic finding before the bone density scan.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryHCV RNA 12 or more weeks after treatment (SVR12)Once, 12 or more weeks after the last doseCompleted todayNot detected: cured
LaboratoryHepatic function panel after treatmentWith the test of cureCompleted todayALT 22, AST 26, alkaline phosphatase 92 U/L, bilirubin 0.8 mg/dL, albumin 4.0 g/dL
LaboratoryBlood count, INR and kidney function in cirrhosisEvery six monthsCompleted todayPlatelets 134, hemoglobin 14.4 g/dL, white cells 5.2; INR 1.0; creatinine 0.88 mg/dL, eGFR 100
ExaminationChild-Pugh class and MELD-NaEvery six months in cirrhosisCompleted todayChild-Pugh A5; MELD-Na 6
ImagingLiver ultrasound for cancer surveillance at six monthsEvery six months in cirrhosisDeferredA deviation: due six months after the baseline scan, in July, but done a week ago, about three weeks late, because the recall was set from the hepatology visit and then held until after the test of cure. No harm resulted: no lesion (LI-RADS US-1). Corrective action: the recall is now set from the date of each scan, every six months
LaboratoryAlpha-fetoprotein with surveillance ultrasoundEvery six months with ultrasoundCompleted today3.4 ng/mL
ImagingNext surveillance ultrasound with alpha-fetoproteinEvery six monthsDueFebruary
ImagingLiver stiffness after cureA year after cure (Baveno VII)DueNext summer, with hepatology
ReferralLiver transplant evaluationWith decompensation or MELD-Na of 15 or moreNot indicatedCompensated; MELD-Na 6
Medication safetyHepatitis A vaccination, dose 2Six months or more after dose 1Completed todayGiven today; series complete
LaboratoryGlucose control: A1c with sensor dataEvery three months when therapy changesCompleted todayA1c 6.3%; glucose management indicator 6.8%; fasting glucose 112 mg/dL
ReferralDiabetic eye examinationYearlyUp to dateDone in June: no retinopathy
Medication safetyZoledronic acidYearlyUp to dateGiven eleven weeks ago; next in nine months, after a calcium check
ExaminationSigns of decompensation (ascites, encephalopathy, jaundice, bleeding)Each visit in cirrhosisCompleted todayNone
Self-managementFalls and fracture riskEach visitCompleted todayNo falls
SurveyAlcohol use (AUDIT-C)Each visit in liver diseaseCompleted todayAUDIT-C 0
SurveyPain score and functionEach visitCompleted today4 of 10; walking 30 minutes
SurveyDepression screen (PHQ-9)At diagnosis and when treatment changesCompleted todayPHQ-9 3

Goal progress:

Immunizations given today: Hepatitis A vaccine, adult, dose 2 of 2 [S]

Guideline basis: AASLD-IDSA HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Simplified HCV treatment algorithm for treatment-naive adults with compensated cirrhosis (2023); AASLD-IDSA HCV Guidance: Monitoring patients who are starting HCV treatment, are on treatment, or have completed therapy (2026); Singal AG, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 2023;78(6):1922-1965 (PMID 37199193) (2023); de Franchis R, et al. Baveno VII - Renewing consensus in portal hypertension. J Hepatol 2022;76(4):959-974 (PMID 35120736) (2022); Kaplan DE, et al. AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology 2024;79(5):1180-1211 (PMID 37870298) (2024); Biggins SW, et al. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the AASLD. Hepatology 2021;74(2):1014-1048 (PMID 33942342) (2021); Crabb DW, et al. Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the AASLD. Hepatology 2020;71(1):306-333 (PMID 31314133) (2019); Rakoski M, Goyal P, Spencer-Safier M, et al. Pain management in patients with cirrhosis. Clin Liver Dis (Hoboken) 2018;11(6):135-140 (PMID 30992804) (2018); Dowell D, et al. CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022. MMWR Recomm Rep 2022;71(3):1-95 (PMID 36327391) (2022); American Diabetes Association. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2026. Diabetes Care 2026;49(Suppl 1):S61-S88 (PMID 41358897) (2026); American Diabetes Association. 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. Diabetes Care 2026;49(Suppl 1):S132-S149 (PMID 41358894) (2026); Watts NB, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012;97(6):1802-1822 (PMID 22675062) (2012); Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions (2018); Adult Immunization Schedule by Medical Condition and Other Indication (2026); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, osteoporosis and depression monographs (2026); Depression and Suicide Risk in Adults: Screening (2023)

Follow-up: Preventive visit next month. Ultrasound with alpha-fetoprotein in February. Hepatology review with liver stiffness a year after cure. Call for abdominal swelling, black stools, vomiting of blood, confusion or yellow eyes. Next scheduled visit 2026-09-21: periodic adult preventive visit. [S]